RosVivo Therapeutics
Junghak Kim is the interim CEO of RosVivo Therapeutics Inc. Prior to joining RosVivo Therapeutics Mr. Kim was the director of Shinwon Investment and Yuyang DNU in South Korea. Mr. Kim brings many years of executive and investment experiences. He has served as a consultant for several multinational companies and raised over $147 million dollars and has managed multiple mergers and acquisitions for his clients.
This person is not in any offices
RosVivo Therapeutics
1 followers
RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. They're using unique scientific insights to develop a new pipeline of first-in-class drugs and diagnostic tests. Their development programs focus on the leading T2D, obesity, and COVID-19 drug candidates.